Antimicrobial Resistant Streptococcus pneumoniae: Prevalence, Mechanisms, and Clinical Implications

American Journal of Therapeutics

Volumn 24, Issue 3, 2017, Pages e361-e369

  Cherazard, Regine ^a   Epstein, Marcia ^b   Doan, Thien Ly ^a   Salim, Tanzila ^a   Bharti, Sheena ^b   Smith, Miriam A ^a  

^a Northwell Health   (United States)

^b NORTH SHORE UNIVERSITY HOSPITAL   (United States)

Author keywords

Antibiotic resistance; Streptococcus pneumoniae

Indexed keywords

ANTIBIOTIC AGENT; BETA LACTAM; COTRIMOXAZOLE; LINCOSAMIDE; MACROLIDE; QUINOLONE DERIVATIVE; TETRACYCLINE DERIVATIVE; ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL GENOME; BACTERIUM ISOLATE; DEVELOPMENT; HUMAN; MEDLINE; MUTATION; NONHUMAN; PENICILLIN RESISTANCE; PHENOTYPE; PREVALENCE; PRIORITY JOURNAL; STREPTOCOCCUS PNEUMONIAE; SYSTEMATIC REVIEW; DRUG EFFECTS; GENETICS; MICROBIOLOGY; MULTIDRUG RESISTANCE; PNEUMOCOCCAL INFECTION;

ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; GENOME, BACTERIAL; HUMANS; MUTATION; PNEUMOCOCCAL INFECTIONS; PREVALENCE; STREPTOCOCCUS PNEUMONIAE;

EID: 85018815975     PISSN: 10752765     EISSN: 15363686     Source Type: Journal    
DOI: 10.1097/MJT.0000000000000551     Document Type: Article

References (62)

1. Tomasz A. Antibiotic resistance in Streptococcus pneumoniae. Clin Infect Dis. 1997;24(suppl 1):S85-S88.
2. Appelbaum PC. Resistance among Streptococcus pneumoniae: implications for drug selection. Clin Infect Dis. 2002; 34:1613-1620.
3. Nuermberger EL, Bishai WR. Antibiotic resistance in Streptococcus pneumoniae: what does the future hold? Clin Infect Dis. 2004;38(suppl 4):S363-S371.
4. Hansman D, Bullen MM. A resistant penumococcus. Lancet. 1967;2:264-265.
5. Hansman D, Glasgow H, Sturt J, et al. Increased resistance to penicillin of pneumococci isolated from man. N Engl J Med. 1971;284:175-177.
6. Weinstein MP, Klugman KP, Jones RN. Rationale for revised penicillin susceptibility breakpoints versus Streptococcus pneumoniae: coping with antimicrobial suceptibility in an era of resistance. Clin Infect Dis. 2009;48: 1596-1600.
7. Cornick JE, Bently SD. Streptococcus pneumoniae: the evolution of antimicrobial resistance to beta-lactams, fluoroquinolones and macrolides. Microbes Infect. 2012;14:573-583.
8. Janoff EN, Musher DM. Streptococcus pneumoniae. In: Bennett JE, Dolin R, Blaser MJ, eds. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases (2310- 27). 8th ed. Philadelphia, PA: Elsevier Saunders; 2015.
9. Linares J, Ardanuy C, Pallares R, et al. Changes in antimicrobial resistance, serotypes and genotypes in Streptococcus pneumoniae over a 30-year period. Clin Microbiol Infect. 2010;16:402-410.
10. Zhanel GG, Dueck M, Hoban DJ, et al. Review of macrolides and ketolides: focus on respiratory tract infections. Drugs. 2001;61:443-498.
11. Niederman MS. Macrolide-resistant pneumococcus in community -acquired pneumonia-is there still a role for macrolide therapy. Am J Resp Crit Care Med. 2015;191: 1216-1217.
12. Jenkins SG, Brown SD, Farrell DJ. Trends in antibacterial resistance among Streptococcus pneumoniae isolated in the U.S.: update from PROTEKT US years 1-4. Ann Clin Microbiol Antimicrob. 2008;7:1.
13. Farrell DJ, Morrissey I, Bakker S, et al. Molecular characterization of macrolide resistance mechanisms among Streptococcus pneumoniae and Streptococcus pyogenes isolated from the PROTEKT 199-2000 study. J Antimicrob Chemother. 2002;50:39-47.
14. Farrell DJ, Morrissey I, Bakker S, et al. Molecular epidemiology of multiresistant Streptococcus pneumoniae with both erm (B) and mef (A) mediated macrolide resistance. J Clin Microbiol. 2004;42:764-768.
15. Jenkins SG, Farrell DJ. Increase in pneumococcus macrolide resistance. United States. Emerg Infect Dis. 2009;15: 1260-1264.
16. Cilloniz C, Albert R, Liapikou A, et al. The effect of macrolide resistance on the presentation and outcome of patients hospitalized for Streptococcus pneumoniae pneumonia. Am J Resp Crit Care Med. 2015;191:1265-1272.
17. Jalava J, Kataja J, Seppala H, et al. In vitro activities of the novel ketolide telithromycin (HMR 3647) against erythromycin-resistant streptococcus species. Antimicrob Agents Chemother. 2001;45:789-793.
18. Birkenmeyer RD, Kagan F. Lincomycin. XI. Synthesis and structure of clindamycin, a potent antibacterial agent. J Med Chem. 1970;13:616-619.
19. Meyers BR, Kaplan K, Weinstein L. Microbiological and pharmacological behavior of 7-Chlorolincomycin. Appl Microbiol. 1969;5:653-657.
20. Steigbigel N. Macrolides and clindamycin. In:Mandell, Douglas and Bennett's Principles and Practice of Infectious Diseases . 4th ed. New York, NY: Churchill Livingstone; 1995:366-382.
21. Klepser ME, Nicolau DP. Bactericidal activity of low-dose clindamycin administered at 8- and 12-hour intervals against Staphylococcus aureus, Streptococcus pneumoniae, and Bacteroides fragilis. Antimicrob Agents Chemother. 1997;41:630-635.
22. Montagnani F, Zanchi A, Stolzuoli L, et al. Clindamycinresistant Streptococcus pneumoniae. Emerg Infect Dis. 2007;13:801-802.
23. Reinert RR. The antimicrobial resistance profile of Streptococcus pneumoniae. Clin Microbiol Infect. 2009;15(suppl 3):7-11.
24. Jones RR, Jacobs MR, Sader HS. Evolving trends in Streptococcus pneumoniae resistance: implications for therapy of community acquired bacterial pneumonia. Int J Antimicrob Agents. 2010;36:197-204.
25. Doern GV, Richter SS, Miller N, et al. Antimicrobial resistance among Streptococcus pneumoniae in the United States: have we begun to turn the corner on resistance to certain antimicrobial classes? Clin Infect Dis. 2005;41: 139-148.
26. Richter SS, Heilmann KP, Dohrn CL, et al. Changing epidemiology of antimicrobial-resistant Streptococcus pneumoniae in the United States, 2004-2005. Clin Infect Dis. 2009;48:e23-33.
27. Jones RN, Sader HS, Mendes RE, et al. Update on antimicrobial susceptibility trends among Streptococcus pneumoniae in the U.S.: report of ceftaroline activity from the SENTRY Antimicrobial Surveillance Program (1998- 2011). Diagn Microbiol Infect Dis. 2013;75:107-109.
28. Megged O, Assous M, Weinberg G, et al. Inducible clindamycin resistance in b-hemolytic streptococci and Streptococcus pneumoniae. Isr Med Assoc J. 2013;15:27-30.
29. Andersson M, MacGowan AP. Development of the quinolones. J Antimicrob Chemother. 2003;51(suppl 1): 1-11.
30. Neuhauser MM, Weinstein RA, Rydman R, et al. Antibiotic resistance among gram-negative bacilli in U.S. intensive care units: implications for fluoroquinolone use. JAMA. 2003;289:885-888.
31. Appelbaum PC, Bhamjee A, Scragg JN, et al. Streptococcus pneumoniae resistant to penicillin and chloramphenicol. Lancet. 1977;2:995-997.
32. Patel S, McGeer A, Melano R. Susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. Antimicrob Agents Chemother. 2011;55:3703-3708.
33. Mandell LA, Wunderink RG, Anqueto A, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of communityacquired pneumonia in adults. Clin Infect Dis. 2007;44 (suppl 2):S27-S72.
34. Chen DK, McGreer A, de Azavedo JC, et al. Decreased susceptibility of Streptococcocus pneumoniae to fluoroquinolones in Canada. N Engl J Med. 1999;341:233-239.
35. Hooper DC, Jacoby GA. Topoisomerase inhibitors: fluoroquinolone mechanisms of action and resistance. Cold Spring Harb Perspect Med. 2016;6. pii:a025320.
36. Smith HJ, Nichol KA, Hoban DJ, et al. Dual activity of fluoroquinolones against Streptococcus pneumoniae: the facts behind the claims. J Antimicrob Chemother. 2002;49: 893-895.
37. Brueggemann AB, Coffman SL, Rhomberg P, et al. Fluoroquinolone resistance in Streptococcus pneumoniae in United States since 1994-1995. Antimicrob Agents Chemother. 2002;46:680-688.
38. Pletz MW, McGee L, Jorgensen J, et al. Levofloxacinresistant invasive Streptococcus pneumoniae in the United States; evidence of clonal spread and the impact of conjugate pneumococcal vaccine. Antimicrob Agents Chemother. 2004;48:3491-3497.
39. Zhanel GG, Walkty A, Nichol K, et al. Molecular characterization of fluoroquinolone resistant Streptococcus pneumoniae clinical isolates obtained from across Canada. Diagn Microbiol Infect Dis. 2003;45:63-67.
40. Jacoby GA. Mechanisms of resistance to quinolones. Clin Infect Dis. 2005;41(suppl 2):S120-S126.
41. Guan X, Xue X, Liu Y, et al. Plasmid-mediated quinolone resistance-current knowledge and future perspectives. J Int Med Res. 2013;41:20-30.
42. Thornsberry C, Brown NP, Draghi DC, et al. Antimicrobial activity among multidrug-resistant Streptococcus pneumoniae isolated in the United States, 2001-2005. Postgrad Med. 2008;120(3 suppl 1):32-38.
43. Heffelfinger JD, Dowell SF, Jorgensen JH, et al. Management of community-acquired pneumonia in the era of pneumococcal resistance: a report from the drugresistant Streptococcus pneumoniae Therapeutic Working Group. Arch Intern Med. 2000;160:1399-1408.
44. Doherty N, Trzcinski K, Pickerill P, et al. Genetic diversity of the tet(M) gene in tetracycline-resistant clonal lineages of Streptococcus pneumoniae. Antimicrob Agents Chemother. 2000;44:2979-2984.
45. Dallas SD, McGee L, Limbago B, et al. Development of doxycycline MIC and disk diffusion interpretive breakpoints and revision of tetracycline breakpoints for Streptococcus pneumoniae. J Clin Microbiol. 2013;51:1798-1802.
46. Fluit AC, Florign A, Verhoef J, et al. Presence of tetracycline resistance determinants and susceptibility to tigecycline and minocycline. Antimicrob Agents Chemother. 2005;49:1636-1638.
47. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. Twentythird informational supplement, M100-S23. Wayne, PA: Clinical and Laboratory Standards Institute; 2013.
48. Jones RN, Stilwell MG, Wilson ML, et al. Contemporary tetracycline susceptibility testing: doxycycline MIC methods and interpretive criteria (CLSI and EUCAST) performance when testing gram-positive pathogens. Diagn Microbiol Infect Dis. 2013;76:69-72.
49. Lederman ER, Gleeson TD, Driscoll T, et al. Doxycycline sensitivity of S. pneumoniae isolates. Clin Infect Dis. 2003; 36:1091.
50. Golden AR, Rosenthal M, Fultz B, et al. Characterization of MDR and XDR Streptococcus pneumoniae in Canada, 2007-13. J Antimicrob Chemother. 2015;70:2199-2202.
51. Lupien A, Gingras H, Leprohon P, et al. Induced tigecycline resistance in Streptococcus pneumoniae mutants reveals mutations in ribosomal protein and rRNA. J Antimicrob Chemother. 2015;70:2973-2980.
52. Houvinen P. Resistance to trimethoprim-sulfamethoxazole. Clin Infect Dis. 2001;32:1608-1614.
53. World Health Organization. Who Model list of essential medicines. 2015. Available at: http://www.who. int/medicines/publications/essentialmedicines/EML- 2015-FINAL-amended-NOV2015.pdf?ua51. Accessed September 21, 2016.
54. Wormser GP, Keusch GT, Heel RC. Co-trimoxazole (trimethoprim-sulfamethoxazole): an updated review of its antibacterial activity and clinical efficacy. Drugs. 1982;24:459-518.
55. Hitchings GH. Mechanism of action of trimethoprimsulfamethoxazole. I. J Infect Dis. 1973;128(suppl):433-436.
56. Burchall JJ. Mechanism of action of trimethoprimsulfamethoxazole. II. J Infect Dis. 1973;128(suppl):437-441.
57. Simberkoff MS, Lukaszewski M, Cross A, et al. Antibioticresistant isolates of Streptococcus pneumoniae from clinical specimens: a cluster of serotype 19A organisms in Brooklyn, New York. J Infect Dis. 1986;153:78-82.
58. Henderson FW, Gilligan PH, Wait K, et al. Nasopharyngeal carriage of antibiotic-resistant pneumococci by children in group day care. J Infect Dis. 1988;157:256-263.
59. Reeves RR, Musher DM. Antibiotic-resistant pneumococcus in a hemophiliac with AIDS. Hosp Pract. 1991;26:81-82.
60. Widdowson CA, Klugman KP. Molecular mechanisms of resistance to commonly used non-beta lactam drugs in. Streptococcus Pneumoniae Semin Respir Infect. 1999;14:255-268.
61. Thornsberry C, Sahm DF, Kelly LJ, et al. Regional trends in antimicrobial resistance among clinical isolates of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States: results from the TRUST Surveillance Program, 1999-2000. Clin Infect Dis. 2002;34(suppl 1):S4-S16.
62. Jacobs MR, Good CE, Windau AR, et al. Activity of ceftaroline against recent emerging serotypes of Streptococcus pneumoniae in the United States. Antimicrob Agents Chemother. 2010;54:2716-2719.